Senetek PLC Presentation at the Rodman and Renshaw Conference


 Exhibit 10.1 
 

 
  
 Acumen BioFin
Rodman & Renshaw 9th Annual Healthcare Conference 
 November 5 – 7, 2007 New York, New York 






 

 
  
 This presentation
contains statements that may be considered ‘forward looking statements’ within the meaning of the Private Securities Litigation Reform Act, including those indicating the financial outlook and projections that might imply commercial
potential and successful evaluation and development of new compounds. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements.
Important factors identified by the Company that it believes could result in such material differences are described in the Company’s Annual Report on Form 10-K for the year 2006. However, the Company necessarily can give no assurance that it
has identified or will identify all of the factors that may result in any particular forward- looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which
may prove to be inaccurate, whether as a result of new information, future events or otherwise. 






 

 
  
 A Specialty Life
Sciences Company Engaged in the Study of Senescence, the Science of Aging with an Initial Focus on Skincare and Dermatological Therapeutics 






 

 
  
 Headed by Professor
Brian Clark, Ph.D., ScD., Senetek PLC’s Chief Scientist 
 ? Achievements: 
 Discovery of the Initiation Codon for Protein Synthesis, 1965/1966 
 First Crystallization of tRNA, 1968 
 Determination of the First Structure of a GTP-Binding Protein, 1985 
 Structural Determination of
the Ternary Complex, 1995 
 Past President of the International Union of Biochemistry and Molecular Biology, 1997 

Head, European Chinese Biotechnology Transfer Task Force 
 ? Publications: 
 Over 200 Papers 

	 5
	  
	 Books 








 

 
  
 World Renowned
Scientific Advisory Board 
 ? Sir John Walker, Ph.D., F.R.S., Scientific Advisor 
 Nobel Prize in Chemistry, 1997 
 Thought Leader in Nutrition & Aging 
 Expert on Mitochondria 
 ? Professor Claudio Francheschi, M.D., EU Project Partner & Science Advisor 
 Professor, University of Bologna and Scientific Director of the Italian National Research Center on Aging-Department of Gerontological
Studies, Bologna, Italy 
 Expert on Inflammation and the Genetics of Aging 
 ? Dr. Gerald Weinstein, M.D. 
 University of California Department of Dermatology, Irvine (Emeritus) 
 World Renowned Expert on
Photo Damaged Skin and Psoriasis 






 

 
  
 Institute of
Experimental Botany—Czech Republic 
 Cooperative Research Agreement to Study Plant Physiology, Genetics and
Biotechnology 
 Institute of Bioorganic Chemistry—Polish Academy of Sciences 
 Polish State Scientific Institution 
 PROTEOMAGE—European Integrated Project 
 Consortium of Leading European Researchers of Healthy
Aging 
 National Hellenic Research Foundation of the Foundation of Biological Research and Biotechnology 
 University of California at Irvine—Department of Dermatology 
 Comprehensive Consulting, Pre-Clinical and Clinical Testing Services for Pharmaceutical and Cosmetic Compounds 






 

 
  
 Over 2000 Patented
and Patent Applied for Compounds 






 

 

	
	 







 

 
  
 Patent Applied
for Suppression of Brain Tumors 
 Currently in Human Clinical Trials in Europe 
 Extraordinary Results for example individual diagnosed with grade 3 glioblastoma multiforme (average life expectancy from diagnosis equals
8 months) treated and alive 24 months post diagnosis 






 

 
  
 1999 Launched
Kinerase® Through ICN/Valeant Pharmaceuticals, the Leading Antiaging Product in the North American Physician Market 
 2004 Licensed Invicorp® to Ardana BioSciences for the European Market 
 2006 Licensed Invicorp® to
Plethora Solutions Holdings Ltd. For the North American Market 
 2006 Transferred Reliaject® to Ranbaxy Pharmaceuticals
for Milestone Payments and Royalties for 15 Years from the Date of First Commercial Sale 
 2006 Entered into Agreement with
Covance Antibody Services for the Distribution of Diagnostic Monoclonal Antibodies 
 2007 Marketing Collaboration for
Pyratine-6TM with Triax Pharmaceuticals 
 “ Strong I ndustry Relationships” 






 

 
  
 No Debt

 Cash on Hand at $20 Million 
 Minimum Guaranteed Revenue Stream of $12 Million in 2008 






 

 
  
 Total 2008 2009
Revenue $ 26,762* $ 13,397 $ 21,891 Gross Margin 25,270 10,492 12,872 
 Operating Income 20,795 1,634 5,017 
 Net Income 18,437 1,549 3,748 EBITDA 17,851 2,262 5,645 

	 *
	  
	 Includes Kinetin Monetization of $24 Million 








 

 
  
 Pyratine-6TM

 4HBAP 






 

 
  
 Baseline Week 12

 Photo Damaged Skin 
 Subject 11—Right 






 

 
  
 Baseline 

Week 12 
 Photo Damaged Skin 
 Subject 26—Right 






 

 
  
 Baseline Week 12

 Acne Rosacea 
 Subject 19 






 

 






 

 






 

 






 

 






 

 
  
 Baseline 

Week 12 
 Photo Damaged Skin 
 Subject 16—Left 






 

 
  
 Baseline Week 12

 Acne Vulgaris/Skin Lightening 
 Subject 32 






 

 
  
 Skin Moisture
Content 4HBAP 






 

 






 

 






 

 
  
 Acne 
 (Investigator Assessment) 4HBAP 






 

 
  
 In Transition

 Yesterday: Outlicensing 
 Today: Marketing Collaborations 
 Higher Revenues 
 Corporate and Brand Recognition 






 

 
  
 Rich Portfolio of
Technology 
 World Class Science 
 Proven Commercial Successes 
 Financially Stable